Published Aug 27, 2024
Adapting Biopharma to AI: A 2024 Update with Greg Meyers
Explore the revolutionary impact of AI in biopharma with Greg Meyers of Bristol Myers Squibb, as he delves into AI-driven advancements in drug discovery, clinical trials, and cancer treatment, while navigating challenges like model bias and workflow transformations, alongside strategic partnerships with tech giants like Nvidia.
Topics covered
Popular Clips
Questions from this episode
- Asked by 40 people
- Asked by 32 people
- Asked by 20 people
- Asked by 14 people
- Asked by 12 people
- Asked by 8 people
- Asked by 8 people
- Asked by 6 people
- Asked by 5 people
- Asked by 5 people
- Asked by 5 people
- Asked by 3 people
- Asked by 3 people
- Asked by 3 people
- Asked by 2 people
Episode Highlights
Related Episodes
Adapting Biopharma to AI with Greg Meyers
Answers 383 questions
Adapting Biopharma to AI with Greg Meyers
Answers 383 questions
AI at the Intersection of Bio with Vijay Pande, Surya Ganguli, and Bowen Liu
Answers 383 questions
AI and Actionable Insights for Drug Development with Daphne Koller
Answers 383 questionsAI in Pharmaceutical R&D with Kim Branson
Answers 383 questionsAI is Here. Now What?
Answers 383 questions
AI + a16z with Vijay Pande
Answers 383 questionsExpert AI as a Healthcare Superpower
Answers 383 questionsBiotech Revolution with Software Engineering Daily
Answers 383 questions
Behind the Buy: Payors and Providers on AI Adoption
Answers 383 questions
Drugging the Undruggable with Greg Verdine
Answers 383 questions
Supercharging Discovery with Evan Feinberg
Answers 383 questions
The Intersection of Biotech x High Tech with Vineeta Agarwala
Answers 383 questionsIRA, AI Regulation, and the Future with Joe Grogan
Answers 383 questions
Network Medicine with Jonathan Swerdlin and Mark Hyman
Answers 383 questions